There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Anti-vascular endothelial growth factor (VEGF) intravitreal agents are the only successful
treatment for wet age-related macular degeneration (AMD). However, there are emerging
signals that anti-VEGF treatment can potentially increase development of geographic
atrophy (GA). Histopathologic, animal, and clinical studies support this hypothesis
although direct proof of a relationship between GA and use of anti-VEGF agents in
neovascular AMD is not yet established. This review presents current evidence supporting
an association between anti-VEGF therapy and progression of geographic atrophy. The
need of exploring alternative methods of treating AMD is indirectly but clearly emphasized.